

Product Data Sheet

Dolastatin 10

Molecular Weight: 785.09

Target: Microtubule/Tubulin; ADC Cytotoxin


Pathway: Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related

Storage: Sealed storage, away from moisture

Powder -80°C 2 years

-20°C 1 year

* The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (127.37 mM)

* "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|-----------|------------|
| | 1 mM | 1.2737 mL | 6.3687 mL | 12.7374 mL |
| | 5 mM | 0.2547 mL | 1.2737 mL | 2.5475 mL |
| | 10 mM | 0.1274 mL | 0.6369 mL | 1.2737 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

| Description | Dolastatin 10 (DLS 10) is a potent antimitotic peptide that inhibits tubulin polymerization. | |
|---------------------------|---|--|
| IC ₅₀ & Target | Auristatin | |
| In Vitro | Dolastatin 10 is a unique pentapeptide that isolated from the sea hare Dolabella auricularia. These in vitro data are quite comparable to those of Dolastatin 10 and Auristatin PE, each of which has GI_{50} values of 10^{-5} - 10^{-6} µg/mL (10^{-2} - 10^{-3} nM) against a similar minipanel of human cell lines ^[2] . The antibody-drug conjugate (ADC) comprises the anti-CD30 monoclonal antibody cAC10 conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), a synthetic analog of the tubulin polymerization inhibitor Dolastatin $10^{[3]}$. MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |

REFERENCES

- $[1]. Pitot \ HC, et \ al. \ Phase \ I \ trial \ of \ dolastatin-10 \ (NSC \ 376128) \ in \ patients \ with \ advanced \ solid \ tumors. \ Clin \ Cancer \ Res. \ 1999 \ Mar; 5(3):525-31.$
- [2]. Pettit GR, et al. Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications ofdolastatin 10. J Nat Prod. 2011 May 27;74(5):962-8.
- [3]. Brentuximab vedotin. Drugs R D. 2011;11(1):85-95.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com